Stoke Therapeutics (STOK) director share sale tied to taxes

Rhea-AI Filing Summary

Stoke Therapeutics, Inc. (STOK) reported insider activity by director Edward M. Kaye, MD. On August 14, 2026, he exercised 26,250 performance stock units, receiving an equal number of common shares and reducing that PSU award to 0. On August 18, 2026, a total of 12,567 common shares were sold in open-market transactions at weighted average prices of $32.01 and $32.47 per share, in each case as an issuer-mandated sale to satisfy tax withholding liabilities related to equity vesting.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 4 txns

Insider Kaye Edward M. MD

Role Director

Sold 12,567 shs ($403K)

Approx. gross sale proceeds $403K

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	11,930	$32.0072	$382K
Sale	Common Stock F1, F3	637	$32.4681	$21K
Exercise	Performance Stock Units F4, F5	26,250	$0.00	$0.00
Exercise	Common Stock	26,250	$0.00	$0.00

Holdings After Transaction: Performance Stock Units — 0 shares (Direct); Common Stock — 124,557 shares (Direct)

Footnotes (5)

1. F1. The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
2. F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.40 to $32.36 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
3. F3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.44 to $32.54 per share, inclusive.
4. F4. Each performance stock unit represents a right to receive one share of the Issuer's common stock.
5. F5. Achievement of this performance stock unit award was certified on August 14, 2025. Pursuant to the terms of the award agreement between the reporting person and the Issuer, half the award vested on August 14, 2025 and the remainder vests on August 14, 2026, subject to the reporting person's continued service to the Issuer on the relevant vesting date.

Key Figures

Common shares sold (first block): 11,930 shares Sale price range (first block): $31.40–$32.36 per share Common shares sold (second block): 637 shares +3 more

6 metrics

Common shares sold (first block) 11,930 shares Common Stock sale on August 18, 2026 at weighted average $32.0072 per share

Sale price range (first block) $31.40–$32.36 per share Price range for 11,930 shares sold in multiple transactions

Common shares sold (second block) 637 shares Common Stock sale on August 18, 2026 at weighted average $32.4681 per share

Sale price range (second block) $32.44–$32.54 per share Price range for 637 shares sold in multiple transactions

PSUs exercised 26,250 units Performance stock units exercised into 26,250 shares of common stock on August 14, 2026

Net shares sold 12,567 shares Net sell volume across reported sale transactions, per transaction summary

Key Terms

performance stock unit, weighted average price, tax withholding liabilities, vesting and settlement, +1 more

5 terms

performance stock unit financial

"Each performance stock unit represents a right to receive one share"

A performance stock unit is a type of reward companies give to employees, usually managers, that depends on how well the company performs over time. If the company hits specific goals, the employee earns shares of stock, like earning a prize for reaching certain levels in a game. It motivates employees to work hard because their rewards are tied to the company's success.

weighted average price financial

"The reported price in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

tax withholding liabilities financial

"sale to satisfy tax withholding liabilities in connection with the vesting"

vesting and settlement financial

"in connection with the vesting and settlement of restricted stock units"

continued service financial

"remainder vests on August 14, 2026, subject to the reporting person's continued service"

FAQ

What insider transactions did STOK director Edward M. Kaye report on this Form 4?

Edward M. Kaye reported exercise of 26,250 performance stock units into common stock on August 14, 2026 and sales of 12,567 common shares on August 18, 2026. The sales were linked to tax withholding obligations from equity vesting.

How many Stoke Therapeutics (STOK) shares did Edward M. Kaye sell, and at what prices?

He sold 11,930 shares at a weighted average price of $32.01 and 637 shares at a weighted average price of $32.47. Footnotes state trades occurred in multiple transactions within disclosed price ranges around those averages.

Were the STOK share sales by Edward M. Kaye discretionary or related to taxes?

The filing states the sales were an Issuer mandated sale to satisfy tax withholding liabilities in connection with vesting and settlement of restricted stock units. This indicates the transactions were tied to tax obligations, not described as discretionary sales.

What happened to Edward M. Kaye’s performance stock units in Stoke Therapeutics (STOK)?

He exercised 26,250 performance stock units, each convertible into one share of common stock, on August 14, 2026. After this exercise, the reported balance of that specific PSU award is 0 units, reflecting full settlement of the award.

How are the weighted average prices for the STOK sales described in the Form 4?

The filing notes the reported prices are weighted average prices. For 11,930 shares, trades ranged from $31.40–$32.36 per share; for 637 shares, trades ranged from $32.44–$32.54 per share, with full breakdowns available on request.

What vesting terms are disclosed for the Stoke Therapeutics (STOK) performance stock unit award?

The company certified achievement of the PSU award on August 14, 2025. According to the award terms, half vested on August 14, 2025 and the remaining half vests on August 14, 2026, subject to continued service with the issuer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/18/2026 - 08:29 PM Accepted by SEC EDGAR 08/18/2026 - 08:28 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaye Edward M. MD

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MASSACHUSETTS 01730

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/14/2026		M		26,250	A	$0	137,124	D
Common Stock	08/18/2026		S(1)		11,930	D	$32.0072(2)	125,194	D
Common Stock	08/18/2026		S(1)		637	D	$32.4681(3)	124,557	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Stock Units	(4)	08/14/2026		M			26,250	(5)	08/14/2026	Common Stock	26,250	$0	0	D

Explanation of Responses:

1. The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.40 to $32.36 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.

3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.44 to $32.54 per share, inclusive.

4. Each performance stock unit represents a right to receive one share of the Issuer's common stock.

5. Achievement of this performance stock unit award was certified on August 14, 2025. Pursuant to the terms of the award agreement between the reporting person and the Issuer, half the award vested on August 14, 2025 and the remainder vests on August 14, 2026, subject to the reporting person's continued service to the Issuer on the relevant vesting date.

	/s/ Jonathan Allan, Attorney-in-Fact	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)